Search

Displaying results 3201 - 3210 of 10000 in total
  1. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and t...

    Products: O. MEPIVACAINE 3% PLAIN. SOLUCION INYECTYABLE, MEPIVASTESIN INJECTION 30 mg/ml
  2. Drug

    XMT-1001

    go.drugbank.com/drugs/DB06069
    Investigational

    It is a water-soluble macromolecular conjugate of camptothecin (CPT). … XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  4. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. … Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.

  5. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.

  6. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion.

  7. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Cefotiam

    go.drugbank.com/drugs/DB00229
    Approved

    One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.

  9. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165] … [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation.

    Products: PIRFENIDONE EG, ESBRIET HARD CAPSULE 267 MG
  10. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. … [L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase